Cervical ultrasonography has no additional value over negative 18F-FDG PET/CT scans for diagnosing cervical lymph node metastases in patients with oesophageal cancer

Lucas Goense 1,2 · Jihane Meziani 1 · Peter S. N. van Rossum 2 · Frank J. Wessels 3 · Marnix G. E. H. Lam 4 · Richard van Hillegersberg 1 · Jelle P. Ruurda 1

Received: 15 March 2017 / Revised: 10 October 2017 / Accepted: 13 October 2017 / Published online: 7 December 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Objectives To investigate the additional value of cervical ultrasonography over 18F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with newly diagnosed oesophageal cancer.

Methods Between January 2013 and January 2016, 163 patients with newly diagnosed oesophageal cancer underwent both cervical ultrasonography and 18F-FDG PET/CT at a tertiary referral centre in the Netherlands. Retrospective clinical data analysis was performed to assess the diagnostic value of cervical ultrasonography and 18F-FDG PET/CT for the detection of cervical lymph node metastases. Fine needle aspiration or clinical follow-up was used as reference standard.

Results The overall incidence of patients with cervical lymph node metastases was 14%. The sensitivity of 18F-FDG PET/CT to detect cervical lymph node metastases was 82% (95% CI 59–94%) and specificity was 91% (95% CI 85–95%). The sensitivity and specificity of cervical ultrasonography were 73% (95% CI 50–88%) and 84% (95% CI 77–90%), respectively. In patients with a negative 18F-FDG PET/CT, 12 of 133 (9%) patients had suspicious nodes on cervical ultrasonography. In all these 12 patients the nodes were confirmed benign.

Conclusions Cervical ultrasonography has no additional diagnostic value to a negative integrated 18F-FDG PET/CT for the detection of cervical lymph node metastases in patients with newly diagnosed oesophageal cancer.

Key Points

- Cervical ultrasonography has no value over PET/CT in evaluating cervical node metastases.
- PET/CT provides greater diagnostic confidence compared to cervical ultrasonography.
- Cervical ultrasonography during standard diagnostic work-up may be considered unnecessary.
- Cervical lesions on PET/CT require cytopathological confirmation by FNA.

Keywords Oesophageal cancer · Cervical ultrasonography · 18F-FDG positron emission tomography/computed tomography · Cancer staging · Cervical lymph node metastases

Introduction

Oesophageal cancer is the eighth most prevalent cancer, and the sixth most common cause of cancer-related death worldwide [1]. Surgical resection of the oesophagus with en bloc lymphadenectomy remains the cornerstone treatment with curative intent for patients with non-metastatic oesophageal cancer [2, 3]. Currently, a multimodal treatment approach is increasingly applied since many studies have shown a survival benefit of neoadjuvant chemoradiotherapy over surgery alone for patients with resectable oesophageal cancer [4–6].

Accurate staging of oesophageal cancer is essential to select patients that are eligible for treatment with curative intent, and to identify patients with distant metastases to prevent a...
non-curative surgical procedure. Currently recommended staging techniques include endoscopic ultrasound (EUS) with fine needle aspiration (FNA), \textsuperscript{18}F-fluorodeoxyglucose (\textsuperscript{18}F-FDG) positron emission tomography (PET) with integrated diagnostic computed tomography (CT) of the neck, chest and abdomen, and cervical ultrasonography with FNA \cite{7}. In some guidelines the use of cervical ultrasonography is recommended since this is considered an effective and accurate approach to assess cervical lymph node involvement \cite{7, 8}. However, the introduction of integrated \textsuperscript{18}F-FDG PET/CT scanning has improved the accuracy of cancer staging by providing both anatomical and metabolic information \cite{9}. Therefore, the additional role of cervical ultrasonography for the detection of cervical lymph node metastases in the current era of routine diagnostic \textsuperscript{18}F-FDG PET/CT imaging may be limited.

Accordingly, the aim of this study was to investigate the additional value of cervical ultrasonography over \textsuperscript{18}F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with newly diagnosed oesophageal cancer.

Methods

Institutional review board approval was obtained, and requirement for written informed consent was waived for this cohort study. In this study all patients referred to our tertiary referral centre with newly diagnosed oesophageal cancer, between January 2013 and January 2016, were identified from a prospectively collected database. Within this cohort, patients who were evaluated with both integrated \textsuperscript{18}F-FDG PET/CT and cervical ultrasonography were included. The two investigations of interest were performed in random order. Cervical lymph nodes with suspected metastasis on the basis of cervical ultrasonography and/or \textsuperscript{18}F-FDG PET/CT underwent FNA and cytological examination. Clinical follow-up data from all patients were collected to identify cervical metastases that were potentially undetected during clinical staging. Therewith, the composite reference standard of the current study included either positive cytopathology of the aspirated material from a suspicious cervical lymph node during initial staging or the occurrence of a new cervical lymph node metastasis that was detected within 12 months of clinical follow-up after initial staging and proven malignant with cytology. Cervical lymph node metastases were grouped into levels corresponding to upper, middle and lower jugular nodes (levels II, III, IV, respectively), and posterior triangle nodes (level V).

After completion of staging, all patients with a clinical stage T1N1–3 or T2–4aN0–3, with no evidence of distant or pathologically confirmed cervical metastases, were scheduled for oesophagectomy with two-field lymphadenectomy.

Cervical ultrasonography with FNA

Ultrasonography of the cervical and supraclavicular region was performed by experienced radiologists, using a 12.5- to 17.5-MHz linear array transducer (Philips Medical Systems, Best, the Netherlands). Cervical lymph nodes with a short axis diameter of at least 5 mm (at least 7 mm for high jugular/level II nodes), or nodes less than 5 mm with a prominent appearance (round shape, loss of fatty hilum, focal low echogenicity or an eccentric mass) and grouped nodes with a short axis diameter of at least 3 mm were considered suggestive of metastasis and cytologically examined after FNA.

Integrated \textsuperscript{18}F-fluorodeoxyglucose PET/CT

Patients had to stay sober for at least 6 h before injection of \textsuperscript{18}F-FDG, and blood glucose levels were measured to check for potential hyperglycaemia. The administered activity of intravenously administered \textsuperscript{18}F-FDG was 2.0 MBq/kg. Approximately 60 min after administration of \textsuperscript{18}F-FDG, PET and CT imaging were performed from neck to abdomen in all patients using a PET/CT system (mCT, Siemens, Erlangen, Germany). Before PET acquisition, a diagnostic quality iodine contrast-enhanced CT was performed using the following settings: 120 kV, 20 mA, 0.5 s tube rotation time, pitch of 1.0 and 3.0 mm slice width. PET was performed using 3-dimensional acquisition, an axial field of view of 216 mm and a scanning time of 3 min/bed position. \textsuperscript{18}F-FDG PET/CT data were reconstructed using iterative ordered subset expectation maximization for 21 subsets and four iterations (Gaussian filter). All \textsuperscript{18}F-FDG PET/CT images were visually interpreted by experienced nuclear medicine physicians. Cervical nodes were considered suspicious on PET/CT if they had increased non-physiological \textsuperscript{18}F-FDG uptake based on visual interpretation without size constraints. Additional FNA was performed in case of suspicious lymph nodes.

Follow-up

The duration of clinical follow-up was calculated from the date of last diagnostic work-up (\textsuperscript{18}F-FDG PET/CT or cervical ultrasonography) until identification of cervical lymph node metastases, last visit at the outpatient clinic or death. The median follow-up of all eligible patients included in this study was 11 months (interquartile range 6–15 months). The time of follow-up of patients without lymph node metastases that were still alive during follow-up was at least 12 months.

Statistical analysis

Sensitivity (SE), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of \textsuperscript{18}F-FDG
PET/CT and cervical ultrasonography for the detection of cervical lymph node metastases were calculated. Sensitivity and specificity were compared using McNemar’s test, and PPV and NPV using the Chi-square test, between 18F-FDG PET/CT and cervical ultrasonography, respectively. The additional value of cervical ultrasonography to 18F-FDG PET/CT was determined by calculating the proportion of patients with a positive cervical ultrasonography that was confirmed malignant, in the group of patients with a negative 18F-FDG PET/CT scan. Differences in diagnostic performance were explored using sensitivity analyses including distant cervical lymph node metastasis (level II), regional cervical lymph node metastasis (level III, IV, V) and squamous cell tumours.

**Results**

Between January 2013 and January 2016 252 patients with newly diagnosed oesophageal cancer were referred to our tertiary referral centre. Of these patients, 89 were excluded because 18F-FDG PET/CT (n = 45) or cervical ultrasonography (n = 36) was not performed, or both cervical ultrasonography and 18F-FDG PET/CT were not performed (n = 8). The main reasons to refrain from cervical ultrasonography of the neck was previous imaging showing distant metastases. In case a 18F-FDG PET/CT was not performed, this was mainly due to the gradual introduction of this imaging modality for this indication in our hospital in the first year of the study period. These patients underwent a CT scan only. A total of 163 patients underwent both cervical ultrasonography and 18F-FDG PET/CT imaging, and were included in the current analysis. Figures 1 and 2 shows the flowchart of patient selection, and Table 1 demonstrates the patient and treatment-related characteristics. The overall incidence of patients with cervical lymph node metastases was 14% (22/163). Of the 22 cervical lymph node metastasis, 2 (9%), 4 (18%), 15 (68%) and 1 (5%) were located in levels II, III, IV and V, respectively.

**Cervical ultrasonography and 18F-FDG PET/CT: non-suspect nodes**

Cervical ultrasonography and 18F-FDG PET/CT were both negative for cervical lymph node metastases in 121 out of 163 (74%) of the patients, and therefore no FNA was performed. During clinical follow-up, four of these 121 patients developed cervical lymph node metastases, which were confirmed malignant after 6, 7, 7 and 12 months, respectively.
Cervical ultrasonography and 18F-FDG PET/CT: suspect nodes

Cervical ultrasonography and 18F-FDG PET/CT were both suggestive of the presence of cervical lymph node metastases in 26 out of 163 (16%) patients. In 24 out of 26 of these patients FNA was performed, of whom 16 were cytologically confirmed malignant and eight were benign. In two patients it appeared impossible to perform FNA because of the small size and inaccessibility of the lymph nodes. These patients underwent primary oesophagectomy with two-field lymphadenectomy and had no signs of cervical metastases after 12 and 19 months of clinical follow-up, respectively. All false positive nodes (18 out of 26) showed increased 18F-FDG uptake and had a short axis diameter ranging between 5 and 10 mm.

Cervical ultrasonography: suspect nodes

In 12 of 163 (7%) patients, only cervical ultrasonography showed suspect cervical lymph nodes, while 18F-FDG PET/CT was negative. FNA showed 10 false positives and two patients had an inconclusive FNA. The patients with inconclusive FNA underwent surgery and had no signs of cervical metastases after 29 and 30 months of clinical follow-up, respectively.

18F-FDG PET/CT: suspect nodes

In four of 163 (3%) patients only 18F-FDG PET/CT was suggestive of cervical lymph node metastases during diagnostic work-up, while cervical ultrasonography was negative. In two patients the suspect nodes were cytologically confirmed malignant (n = 1) or benign (n = 1) after FNA. In the other two patients FNA was not performed. In one of these patients a CT scan showed enlargement of the cervical lymph node 3 months after initial diagnostic work-up, which was therefore considered malignant. This patient underwent definitive chemoradiotherapy and died a few months after diagnosis of the cervical metastasis. The other patient underwent surgery and showed no cervical metastases during the first 18 months of clinical follow-up.

Diagnostic performance

The comparison of diagnostic performance between 18F-FDG PET/CT and cervical ultrasonography to detect malignant...
lymph nodes and subsequent subgroup analysis are summarized in Table 2. The sensitivity and specificity of 18F-FDG PET/CT was 82% (95% CI 59–94%) and 91% (95% CI 85–95%), respectively. Positive and negative predictive values of 18F-FDG PET/CT were 60% (95% CI 41–77%) and 97% (95% CI 23–59%), respectively. The sensitivity of cervical ultrasonography was 73% (95% CI 50–88%), whereas the specificity was 84% (95% CI 77–90%). Positive and negative predictive values of cervical ultrasonography were 42% (95% CI 27–59%) and 95% (95% CI 41–73%), respectively (Table 2). Both sensitivity and specificity were significantly higher for 18F-FDG PET/CT scanning compared to cervical ultrasonography. In the various subgroup analyses, ultrasonography did not outperform 18F-FDG PET/CT scanning for the detection of cervical lymph node metastasis. Overall, there was no (0% [0/133]) additional value of a cervical ultrasonography to a negative 18F-FDG PET/CT scan for the detection of cervical lymph node metastases.

Discussion

In the current cohort study the additional diagnostic value of cervical ultrasonography to 18F-FDG PET/CT scanning for the detection of cervical lymph node metastases in patients with newly diagnosed oesophageal cancer was evaluated. Results from the current cohort of patients demonstrated no additional value of cervical ultrasonography to integrated 18F-FDG PET/CT scanning.

Several studies suggest that in case of cervical lymph node involvement an aggressive approach with radical oesophagectomy combined with a three-field lymphadenectomy is justified [10]. However, in most Northern American and European countries, presence of cervical lymph node metastases is still considered as systemic disease. Therefore, it is argued that survival will not increase despite removal of these lymph nodes. In that case different palliative therapies are applied for patients with cervical lymph node metastases [11, 12]. Because the presence of cervical lymph node metastases will have a major influence on both prognosis and therapeutic decisions, accurate diagnosis of cervical lymph node metastasis is crucial.

Integrated 18F-FDG PET/CT scanning has significantly improved the accuracy of oesophageal cancer staging and frequently influences patient management [13]. Therefore, the use of integrated 18F-FDG PET/CT is currently highly recommended in initial oesophageal cancer staging [13]. Owing to the improvement in oesophageal cancer staging by 18F-FDG PET/CT scanning, it has been suggested that the additional role of cervical ultrasonography for the detection of cervical lymph node metastasis may be limited [14]. This hypothesis was confirmed in the current cohort of patients in which no additional value of cervical ultrasonography was found to

| Table 2  | Comparison of diagnostic parameters of 18F-FDG PET/CT and cervical ultrasonography, including subgroup analysis |
|----------|----------------------------------------------------------------------------------------------------------|
|          | 18F-FDG PET/CT                                           | Cervical ultrasonography | P value |
| Overall  | SE (%) [95% CI]                                         | 18/22 (82%) [59–94]     | 16/22 (73%) [50–88] | 0.012 |
|          | SP (%) [95% CI]                                         | 129/141 (91%) [85–95]   | 119/141 (84%) [77–90] | 0.013 |
|          | PPV (%) [95% CI]                                        | 18/30 (60%) [41–77]     | 16/38 (42%) [27–59] | 0.222 |
|          | NPV (%) [95% CI]                                        | 129/133 (97%) [23–59]   | 119/125 (95%) [41–73] | 0.675 |
| Squamous cell carcinomas | SE (%) [95% CI]                                         | 7/9 (78%) [40–97]       | 6/9 (67%) [30–92] | 0.289 |
|          | SP (%) [95% CI]                                         | 52/57 (91%) [81–97]     | 47/57 (82%) [70–91] | 0.063 |
|          | PPV (%) [95% CI]                                        | 7/13 (58%) [36–77]      | 6/16 (38%) [22–55] | 0.477 |
|          | NPV (%) [95% CI]                                        | 52/54 (96%) [88–99]     | 47/50 (94%) [86–98] | 0.929 |
| Level III, IV, V lesions | SE (%) [95% CI]                                         | 17/20 (85%) [62–97]     | 15/20 (75%) [51–91] | 0.008 |
|          | SP (%) [95% CI]                                         | 127/135 (94%) [87–97]   | 118/135 (87%) [81–92] | 0.012 |
|          | PPV (%) [95% CI]                                        | 17/25 (68%) [51–81]     | 15/32 (47%) [35–60] | 0.185 |
|          | NPV (%) [95% CI]                                        | 127/130 (98%) [93–99]   | 118/122 (96%) [92–98] | 0.932 |
| Level II lesions | SE (%) [95% CI]                                         | 2/3 (67%) [9–99]        | 2/3 (67%) [9–99] | 1.000 |
|          | SP (%) [95% CI]                                         | 119/123 (97%) [92–99]   | 118/123 (96%) [91–99] | 1.000 |
|          | PPV (%) [95% CI]                                        | 2/6 (33%) [3–64]        | 2/7 (29%) [11–56] | 0.852 |
|          | NPV (%) [95% CI]                                        | 119/120 (99%) [96–100]  | 118/119 (99%) [96–100] | 0.995 |

TP true positive, TN true negative, FP false positive, FN false negative, SE sensitivity, SP specificity, PPV positive predictive value, NPV negative predictive value
integrated 18F-FDG PET/CT scanning for the detection of cervical metastasis. With regard to sensitivity, specificity, PPV and NPV of both diagnostic modalities (Table 2), 18F-FDG PET/CT scanning performed better on all these domains compared to cervical ultrasonography. Even though cervical ultrasonography yielded a NPV of 95%, this did not result in an additional value over 18F-FDG PET/CT which yielded an even higher NPV of 97%. Also, no subgroup in which ultrasonography outperformed 18F-FDG PET/CT scanning for the detection of cervical metastasis could be identified. However, suspected cervical lesions detected with 18F-FDG PET/CT still require cytopathological confirmation by FNA because of possible false positives (encountered in 12 of 163 [7%] patients in the current study).

Our results are consistent with two articles in the literature that reported no additional value of cervical ultrasonography to integrated 18F-FDG PET/CT scanning (or standalone PET combined with CT) for detecting cervical lymph node metastases (n = 170 and n = 136, respectively) [14, 15]. One study found an additional value of 4% (3/74) of cervical ultrasonography over standalone PET and CT imaging (n = 109) [16]. Methodological differences between the various studies could explain some of the discrepancies in reported added value of cervical ultrasonography. First, two studies only assessed standalone PET and CT [15, 16]. This may have led to an underestimation of the diagnostic value of PET/CT, as standalone PET and CT may result in lower diagnostic accuracies compared to integrated 18F-FDG PET/CT scanning. To this regard, the only study so far that used integrated 18F-FDG PET/CT scanning demonstrated no additional value of cervical ultrasonography for the detection of cervical lymph node metastases [14]. The current study was able to confirm these results in an independent set of patients, which suggests external generalizability to other patient populations. Second, criteria for positive cervical lymph nodes on both 18F-FDG PET/CT and cervical ultrasonography were heterogeneous throughout the different studies, and were often operator-dependent [14–16]. However, the results of the current study and those present in the current literature represent cervical lymph node staging in daily practice [14–16].

In the current cohort study, the incidence of cervical lymph node metastases was 14% (22/163). This rate is high compared to the other studies assessing the additional value of cervical ultrasonography, which reported incidences of cervical lymph node metastases ranging between 3% and 9% [14–16]. This difference can be explained by the fact that the current study included a relatively high number of proximal (13%) and squamous cell tumours (40%) compared to the other studies. It is well known that these types of tumours, at these locations, have a higher incidence of cervical lymph node metastases [17]. Even higher incidences of 27–31% have been described in case extensive pathological examination is performed after three-field lymph node dissection [18, 19].

Potential limitations apply to this study. First, in our cohort study the image analysts were not blinded to the results of earlier conducted investigations, which may have influenced the interpretation of the different tests. Second, cervical lymph node metastasis may have been missed by both imaging modalities, as no pathological evaluation was available for patients with a negative test. These patients were evaluated by clinical follow-up, which is a potentially less reliable reference test. To this regard, differential verification bias was of concern in the current study because different reference standards were used for the detection of cervical lymph nodes [20]. Third, the time interval (e.g. 6 or 12 months) in which positive findings at follow-up are regarded as false negatives influences the diagnostic values of the different modalities. Changing the time interval of the current study from 12 to 6 months, for example, would have resulted in an overestimation of the reported sensitivities of both modalities. However, in the current study changing the time interval to 6 months would not have influenced the added value of cervical ultrasonography over 18F-FDG PET/CT.

In conclusion, this study demonstrates that cervical ultrasonography has no additional diagnostic value over a negative 18F-FDG PET/CT for the detection of cervical lymph node metastases in patients with newly diagnosed oesophageal cancer. Especially since the introduction of integrated 18F-FDG PET/CT systems, cervical ultrasonography during standard diagnostic work-up of oesophageal cancer patients may be considered unnecessary. Suspected cervical lesions on 18F-FDG PET/CT still require cytopathological confirmation by FNA because of possible false positive results.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Dr. J.P. Ruurd.

Conflict of interest The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Funding The authors state that this work has not received any funding.

Statistics and biometry Two of the authors have significant statistical expertise.

Ethical approval Institutional review board approval was obtained.

Informed consent Written informed consent was waived by the institutional review board.
Methodology

- retrospective
- diagnostic
- observational
- performed at one institution

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252
3. Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381:400–412
4. Shapiro J, van Lanschot JJ, Hulshof MC et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098
5. Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692
6. Jang R, Darling G, Wong RK (2015) Multimodality approaches for the curative treatment of esophageal cancer. J Natl Compr Canc Netw 13:229–238
7. Association of Comprehensive Cancer Centers (2010) Oesophageal carcinoma. Comprehensive Cancer Center, the Netherlands. http://www.oncoline.nl/oesofaguscarcinoom. Accessed 13 Feb 2015
8. Leng XF, Zhu Y, Wang GP, Jin J, Xian L, Zhang YH (2016) Accuracy of ultrasound for the diagnosis of cervical lymph node metastasis in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis 8:2146–2157
9. Torrance AD, Almond LM, Fry J, Wadley MS, Lyburn ID (2015) Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer? Surgeon 13:19–33
10. Lerut T, Nafeux P, Moons J et al (2004) Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 240:962–972 discussion 972-4
11. Zhang P, Xi M, Zhao L et al (2014) Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone. Radiat Oncol 9:256–259
12. Eldeeb H, Hamed RH (2012) Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin: the impact of chemoradiotherapy. Chin J Cancer 31:484–490
13. van Rossum PS, van Lier AL, Lips IM et al (2015) Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clin Radiol 70:81–95
14. Blom RL, Vliegen RF, Schreurs WM et al (2012) External ultrasonography of the neck does not add diagnostic value to integrated positron emission tomography-computed tomography (PET-CT) scanning in the diagnosis of cervical lymph node metastases in patients with esophageal carcinoma. Dis Esophagus 25:555–559
15. Schreurs LM, Verhoeof CC, van der Jagt EJ, van Dam GM, Groen H, Plukker JT (2008) Current relevance of cervical ultrasonography in staging cancer of the esophagus and gastroesophageal junction. Eur J Radiol 67:105–111
16. Omloo JM, van Heijl M, Smits NJ et al (2009) Additional value of external ultrasonography of the neck after CT and PET scanning in the preoperative assessment of patients with esophageal cancer. Dig Surg 26:43–49
17. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y (1994) Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220:364–372 discussion 372-3
18. Natsugoe S, Yoshinaka H, Shimada M et al (1999) Assessment of cervical lymph node metastasis in esophageal carcinoma using ultrasonography. Ann Surg 229:62–66
19. Shiozaki H, Yano M, Tsujinaka T et al (2001) Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer. Dis Esophagus 14:191–196
20. Lijmer JG, Mol BW, Heisterkamp S et al (1999) Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282:1061–1066